Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

IL-33 Is a Cell-Intrinsic Regulator of Fitness during Early B Cell Development.

Stier MT, Mitra R, Nyhoff LE, Goleniewska K, Zhang J, Puccetti MV, Casanova HC, Seegmiller AC, Newcomb DC, Kendall PL, Eischen CM, Peebles RS Jr.

J Immunol. 2019 Sep 15;203(6):1457-1467. doi: 10.4049/jimmunol.1900408. Epub 2019 Aug 7.

PMID:
31391233
2.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK.

Blood Adv. 2019 May 14;3(9):1540-1545. doi: 10.1182/bloodadvances.2019000090.

3.

The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms.

Seegmiller AC, Hsi ED, Craig FE.

Cytometry B Clin Cytom. 2019 Jan;96(1):20-29. doi: 10.1002/cyto.b.21756. Epub 2018 Dec 13. Review.

PMID:
30549186
4.

Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up.

Wheeler FC, Kim AS, Mosse CA, Shaver AC, Yenamandra A, Seegmiller AC.

Am J Clin Pathol. 2018 Mar 29;149(5):418-424. doi: 10.1093/ajcp/aqy002.

5.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC.

Leuk Res. 2018 Feb;65:67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2.

6.

A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.

Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O.

Am J Hematol. 2018 Aug;93(4):504-510. doi: 10.1002/ajh.25018. Epub 2018 Jan 25.

7.

B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.

Shaver AC, Seegmiller AC.

Clin Lab Med. 2017 Dec;37(4):771-785. doi: 10.1016/j.cll.2017.07.005. Epub 2017 Aug 31. Review.

PMID:
29128068
8.

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Shaver AC, Seegmiller AC.

Curr Hematol Malig Rep. 2017 Oct;12(5):448-454. doi: 10.1007/s11899-017-0405-y. Review.

PMID:
28822050
9.

Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, Wei P, Tang G, Seegmiller AC, Reddy NM, Yin CC, Wang W, Xu J, Miranda RN, Zuo Z, Li S.

Mod Pathol. 2017 Dec;30(12):1688-1697. doi: 10.1038/modpathol.2017.93. Epub 2017 Aug 4.

10.

A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Keeney M, Wood BL, Hedley BD, DiGiuseppe JA, Stetler-Stevenson M, Paietta E, Lozanski G, Seegmiller AC, Greig BW, Shaver AC, Mukundan L, Higley HR, Sigman CC, Kelloff G, Jessup JM, Borowitz MJ.

Cytometry B Clin Cytom. 2018 Mar;94(2):239-249. doi: 10.1002/cyto.b.21528. Epub 2017 May 5.

11.

Data-Driven Iterative Refinement of Bone Marrow Testing Protocols Leads to Progressive Improvement in Cytogenetic and Molecular Test Utilization.

Seegmiller AC, Kim AS, Mosse CA, Shaver AC, Thompson MA, Li S, Head DR, Zutter MM.

Am J Clin Pathol. 2016 Nov 1;146(5):585-593. doi: 10.1093/ajcp/aqw180.

PMID:
27769956
12.

High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy.

Ferrell PB Jr, Diggins KE, Polikowsky HG, Mohan SR, Seegmiller AC, Irish JM.

PLoS One. 2016 Apr 13;11(4):e0153207. doi: 10.1371/journal.pone.0153207. eCollection 2016.

13.

CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.

Wang XJ, Seegmiller AC, Reddy NM, Li S.

Eur J Haematol. 2016 Jul;97(1):39-47. doi: 10.1111/ejh.12680. Epub 2015 Oct 1.

PMID:
26340843
14.

B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model.

Shaver AC, Greig BW, Mosse CA, Seegmiller AC.

Am J Clin Pathol. 2015 May;143(5):716-24. doi: 10.1309/AJCPOOJRAVUN75GD.

PMID:
25873506
15.

Polyunsaturated fatty acid supplementation reverses cystic fibrosis-related fatty acid abnormalities in CFTR-/- mice by suppressing fatty acid desaturases.

Njoroge SW, Laposata M, Boyd KL, Seegmiller AC.

J Nutr Biochem. 2015 Jan;26(1):36-43. doi: 10.1016/j.jnutbio.2014.09.001. Epub 2014 Oct 2.

PMID:
25448610
16.

Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.

Seegmiller AC.

Int J Mol Sci. 2014 Sep 11;15(9):16083-99. doi: 10.3390/ijms150916083. Review.

17.

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.

Li S, Seegmiller AC, Lin P, Wang XJ, Miranda RN, Bhagavathi S, Medeiros LJ.

Mod Pathol. 2015 Feb;28(2):208-17. doi: 10.1038/modpathol.2014.95. Epub 2014 Aug 8.

18.

Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase.

Umunakwe OC, Seegmiller AC.

J Lipid Res. 2014 Jul;55(7):1489-97. doi: 10.1194/jlr.M050369. Epub 2014 May 24.

19.

Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach.

Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Marx ER, Sinkfield KJ, Pollard HN, Plummer WD, Dupont WD, Shultz EK, Dittus RS, Stead WW, Santoro SA, Zutter MM.

Am J Clin Pathol. 2013 Nov;140(5):643-50. doi: 10.1309/AJCP8CKE9NEINQFL.

20.

Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms.

Seegmiller AC, Wasserman A, Kim AS, Kressin MK, Marx ER, Zutter MM, Mosse CA.

Leuk Lymphoma. 2014 Mar;55(3):601-5. doi: 10.3109/10428194.2013.801470. Epub 2013 Aug 28.

PMID:
23876099
21.

Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process?

Slone JS, Smith MC, Seegmiller AC, Sidonio RF, Yang E.

J Pediatr Hematol Oncol. 2013 Oct;35(7):559-65. doi: 10.1097/MPH.0b013e31829cdea0.

PMID:
23799525
22.

Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis.

Katrangi W, Lawrenz J, Seegmiller AC, Laposata M.

Lipids. 2013 Apr;48(4):333-42. doi: 10.1007/s11745-013-3768-4. Epub 2013 Feb 27.

PMID:
23440519
23.

Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.

Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, Díez-Martín JL, Liu JJ, Miranda RN, Montoto S, Nanaji NM, Navarro JT, Seegmiller AC, Vose JM.

Cancer. 2012 Nov 1;118(21):5270-7. doi: 10.1002/cncr.27551. Epub 2012 Apr 17.

24.

DHA and EPA reverse cystic fibrosis-related FA abnormalities by suppressing FA desaturase expression and activity.

Njoroge SW, Laposata M, Katrangi W, Seegmiller AC.

J Lipid Res. 2012 Feb;53(2):257-65. doi: 10.1194/jlr.M018101. Epub 2011 Nov 16.

25.

Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis.

Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP.

Transfusion. 2012 Jan;52(1):4-5. doi: 10.1111/j.1537-2995.2011.03407.x. Epub 2011 Oct 27. No abstract available.

PMID:
22032241
26.

Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.

Seegmiller AC, Wang HY, Hladik C, Chen W.

Arch Pathol Lab Med. 2011 Jun;135(6):770-5. doi: 10.1043/2009-0691-OA.1.

PMID:
21631271
27.

Increased Δ5- and Δ6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis.

Njoroge SW, Seegmiller AC, Katrangi W, Laposata M.

Biochim Biophys Acta. 2011 Jul-Aug;1811(7-8):431-40. doi: 10.1016/j.bbalip.2011.05.002. Epub 2011 May 13.

PMID:
21605700
28.

Increased elongase 6 and Δ9-desaturase activity are associated with n-7 and n-9 fatty acid changes in cystic fibrosis.

Thomsen KF, Laposata M, Njoroge SW, Umunakwe OC, Katrangi W, Seegmiller AC.

Lipids. 2011 Aug;46(8):669-77. doi: 10.1007/s11745-011-3563-z. Epub 2011 May 5.

29.

Elucidation of seventeen human peripheral blood B-cell subsets and quantification of the tetanus response using a density-based method for the automated identification of cell populations in multidimensional flow cytometry data.

Qian Y, Wei C, Eun-Hyung Lee F, Campbell J, Halliley J, Lee JA, Cai J, Kong YM, Sadat E, Thomson E, Dunn P, Seegmiller AC, Karandikar NJ, Tipton CM, Mosmann T, Sanz I, Scheuermann RH.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S69-82. doi: 10.1002/cyto.b.20554.

30.

Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.

Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W.

Mod Pathol. 2010 Jul;23(7):909-20. doi: 10.1038/modpathol.2010.76. Epub 2010 Mar 26.

31.

Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.

Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW.

Am J Clin Pathol. 2009 Dec;132(6):940-9. doi: 10.1309/AJCP8G5RMTWUEMUU.

PMID:
19926587
32.

Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature.

Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W.

Am J Clin Pathol. 2009 Oct;132(4):597-605. doi: 10.1309/AJCPFUR1BK0UODTS. Review.

PMID:
19762538
33.

Bright CD38 expression is an indicator of MYC rearrangement.

Maleki A, Seegmiller AC, Uddin N, Karandikar NJ, Chen W.

Leuk Lymphoma. 2009 Jun;50(6):1054-7. doi: 10.1080/10428190902930470. No abstract available.

PMID:
19455464
34.

Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes.

Seegmiller AC, Karandikar NJ, Kroft SH, McKenna RW, Xu Y.

Cytometry B Clin Cytom. 2009 May;76(3):169-74. doi: 10.1002/cyto.b.20459.

35.

Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma.

Seegmiller AC, Xu Y, McKenna RW, Karandikar NJ.

Am J Clin Pathol. 2007 Feb;127(2):176-81.

PMID:
17210522
36.

Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila.

Dobrosotskaya IY, Seegmiller AC, Brown MS, Goldstein JL, Rawson RB.

Science. 2002 May 3;296(5569):879-83.

37.

The SREBP pathway in Drosophila: regulation by palmitate, not sterols.

Seegmiller AC, Dobrosotskaya I, Goldstein JL, Ho YK, Brown MS, Rawson RB.

Dev Cell. 2002 Feb;2(2):229-38.

38.

Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells.

Sakai J, Rawson RB, Espenshade PJ, Cheng D, Seegmiller AC, Goldstein JL, Brown MS.

Mol Cell. 1998 Oct;2(4):505-14.

Supplemental Content

Loading ...
Support Center